Wayland Group Ltd is a Canada-based, licensed producer of cannabis and hemp-derived products, traded over the counter under the symbol MRRCF. The company operates under Health Canada’s regulations for cultivation, processing and distribution of medical-grade cannabis. Through its Canadian facilities, Wayland develops smokable flower, oils and vape formulations designed to meet patient needs and comply with stringent quality-control standards.
In Europe, Wayland Group has pursued a strategy of establishing GMP-certified operations to address growing medical cannabis demand. Its German subsidiary operates greenhouse cultivation and post-harvest processing facilities that are designed to serve patients under Germany’s national medical cannabis program. The company is also exploring additional licenses and partnerships in other regulated markets, including the United Kingdom and select Caribbean jurisdictions, in order to expand its global footprint.
On the product development side, Wayland invests in research and development of novel cannabinoid formulations, delivery mechanisms and extraction processes. By combining in-house cultivation expertise with third-party research collaborations, the company aims to create differentiated products for both medical and wellness markets. Its extraction initiatives focus on producing high-purity concentrates and isolate derivatives for use in tinctures, topicals and capsule formats.
Founded in the mid-2010s, Wayland Group is led by a management team with backgrounds in pharmaceuticals, agriculture and regulatory affairs. Chief Executive Officer Oliver Vogt heads operations, supported by a leadership team that includes experts in cultivation science, quality assurance and international business development. The company continues to pursue regulatory approvals and market entry across multiple jurisdictions as part of its long-term growth strategy.
AI Generated. May Contain Errors.
Free MRRCF Stock Alerts